BLUEPRINT MEDICINES CORP (BPMC)       45.65  -3.41 (-6.95%)

45.65  -3.41 (-6.95%)

US09627Y1091 - Common Stock - After market: 45.65 0 (0%)

News Image
2 days ago - Blueprint Medicines Corporation

Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of...

News Image
13 days ago - Blueprint Medicines Corporation

Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's...

News Image
a month ago - Blueprint Medicines Corporation

Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors. Dr. Tsai, who was...

News Image
a month ago - Blueprint Medicines Corporation

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

News Image
2 months ago - Seeking Alpha

COGT stock initiated Buy at Needham citing a better profile for cancer drug (NASDAQ:COGT)

Needham issued a Buy rating on Cogent Biosciences (COGT) on Wednesday, citing better prospects for its systemic mastocytosis candidate bezuclastinib. Read the full story here.

News Image
2 months ago - Seeking Alpha

BPMC stock initiated Buy at Needham on sales prospects for cancer therapy (NASDAQ:BPMC)

Needham launched its coverage on Blueprint Medicines Corporation (BPMC) on Wednesday with a Buy recommendation, citing sales potential of its cancer medication Ayvakit. Read full story here.

News Image
2 months ago - Seeking Alpha

Blueprint Ayvakit shows response in long term data; elenestinib shows promise in phase 1

Blueprint Medicines (BPMC) reported long term updated of Ayvakit from the PATHFINDER and EXPLORER trials in patients with advanced systemic mastocytosis ((SM)) and part of 1 of...

News Image
2 months ago - Blueprint Medicines Corporation

Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis

-- 95 percent confirmed overall response rate and 37 percent confirmed complete remission rate in treatment-naïve patients with SM-AHN, the most common subtype...

News Image
2 months ago - Blueprint Medicines Corporation

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

News Image
2 months ago - Blueprint Medicines Corporation

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug...

News Image
3 months ago - Blueprint Medicines Corporation

Blueprint Medicines to Present at Upcoming Investor Conferences

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

News Image
3 months ago - Blueprint Medicines Corporation

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

News Image
4 months ago - Market News Video

First Week of BPMC December 16th Options Trading

News Image
4 months ago - SBWire

NASDAQ:BPMC Investor Notice: Investigation over Potential Wrongdoing at Blueprint Medicines Corporation

San Diego, CA -- (SBWIRE) -- 10/12/2022 -- Certain directors of Blueprint Medicines Corporation are under investigation over potential breaches of fiduciary duties.

News Image
4 months ago - Blueprint Medicines Corporation

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

News Image
5 months ago - Blueprint Medicines Corporation

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

News Image
5 months ago - NewMediaWire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image
5 months ago - SBWire

Blueprint Medicines Corporation (NASDAQ:BPMC) Investor Notice: Investigation over Possible Violations of Securities Laws

San Diego, CA -- (SBWIRE) -- 08/30/2022 -- Blueprint Medicines Corporation is under investigation over potential securities laws violations in connection with certain financial statements.

News Image
5 months ago - Rosen Law Firm, P.A.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of...